Case Report

Unique Growth Pattern Presentation of a Papillary Renal Cell Carcinoma

Octavia Oana Harich 1,† , Gheorghe-Emilian Olteanu 2,3,† , Ioana Maria Mihai 4,*, Marius Benta 5,6 , Gavriliuc Oana Isabella 7,8 , Paunescu Virgil 7,8 and Florina Maria Bojin 7,8

1 Department of Functional Sciences, “Vctor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania
2 Department of Infectious Diseases, Discipline of Pulmonology, Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, “Vctor Babes” University of Medicine and Pharmacy, Timisoara Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania
3 Center of Expertise for Rare Lung Diseases, Clinical Hospital of Infectious Diseases and Pneumothiologis “Dr. Vctor Babes” Timisoara, Gh. Adam Street No. 13, 300310 Timisoara, Romania
4 Department of Microscopic Morphology, Discipline of Morphopathology, Anapatmol Research Center, “Vctor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania
5 Timis County Emergency Clinical Hospital “Pius Brînzeu” Timisoara, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania
6 XVision AI, Calea Torontalului No. 69, 021923 Timisoara, Romania
7 Department of Functional Sciences, Immuno-Physiology and Biotechnologies Center, “Vctor Babes” University of Medicine and Pharmacy, Eftimie Murgu Sq. No. 2, 300041 Timisoara, Romania
8 Timis County Emergency Clinical Hospital “Pius Brînzeu” Timisoara, Center for Gene and Cellular Therapies in the Treatment of Cancer—OncoGen, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania
* Correspondence: ioana.mihai@umft.ro
† These authors contributed equally to this work.

Abstract: Papillary renal cell carcinoma (PRCC) is defined by the WHO 2022 classification as a malignant tumor derived from the renal tubular epithelium. However, the WHO 2016 classification subdivided PRCC into two types, with type 1 PRCC showing papillae covered by a single layer of neoplastic cells, and type II PRCC, which can show multiple types of histologies and is more aggressive. The WHO 2022 classification eliminated the subcategorization of PRCC. Here, we present a histopathological case study with a 4-year follow-up diagnosed in 2018 as type I PRCC (WHO 2016) with intra-pyelocalyceal growth pattern in a 59-year-old male patient with a history of Type II diabetes mellitus, left-sided renal–ureteral lithiasis, and benign hypertrophy of the prostate. Microscopically the tumor was composed of small cuboidal cells with inconspicuous nucleoli, arranged on a single layer of tubulo-papillary cores, and scant, foamy macrophages. The tumor had a non-infiltrative, expansive pyelo-locyceal growth pattern. Immunohistochemically (IHC), the tumor cells were CK7-intense and diffusely positive, and stained granular for AMACR. Next-generation sequencing (NGS) was performed for the tumor and the normal adjacent tissue for in-depth pathological characterization. To our knowledge, this is the first reported case where a PRCC displays this unique intra-pyelocalyceal growth pattern, mimicking a urothelial cell carcinoma of the renal pelvis system.

Keywords: papillary renal cell carcinoma; growth pattern; IHC; NGS

1. Introduction

Papillary renal cell carcinoma (PRCC) is mainly associated with end-stage renal disease (ESRD) with scarring or acquired cystic disease. Even if rare, some genetic syndromes are associated with PRCC, e.g., Birt–Hogg–Dubé syndrome. In addition, the hereditary PRCC syndrome presents with a high degree of penetrance in the families affected by it [1]. An in-depth molecular characterization analysis, published by the Cancer Genome Atlas Research Network (TCGA) [2], showed that type 1 and type 2 PRCC are not only...
histologically distinct but are also biologically and clinically divergent. Type 1 PRCC is associated with tyrosine-protein kinase (MET) pathway alterations, while type 2 PRCC is linked with activation of the nuclear factor erythroid 2-related factor 2/antioxidant responsive element (Nrf2-ARE) pathway. Furthermore, type 2 PRCC can be subdivided into at least three subtypes, based on molecular and distinctive phenotypic features [2].

PRCC remains the second most commonly encountered morphotype of renal cell carcinoma (RCC), with clear-cell renal-cell carcinoma (ccRCC) being the most common. Overall, when compared with clear-cell RCC, PRCC presents with a significantly higher rate of organ-confined tumor staging (pT1-2N0M0), and a higher five-year cancer-specific survival (CSS). In most of the cases, type 1 PRCC tumors show an exophytic spherical growth pattern, with pseudo-necrotic changes and/or the presence of a pseudo-capsule, all of which can be considered to be typical signs of a type 1 PRCC [3]. The histopathological review of PRCC presents a high degree of heterogeneity with regards to PRCC type 2, which can present with multiple types of histologies as opposed to PRCC type 1 which has a distinct specific histology and is generally diagnosed on hematoxylin and eosin (H&E) stains alone [2,3]. In 2022, in the fifth edition of the WHO Classification of Tumors of the Urinary and Male Genital Systems [4] the subcategorization of PRCC was eliminated and a single malignant entity was maintained, i.e., PRCC with no further divisions into type 1 or type 2. This elimination was implemented because of the frequent identification of tumors with mixed histologies (i.e., phenotypes), and the tumor entities that subdivided the type 2 PRCC category, because of this, from hereafter, the tumor in our case will be referred to as a PRCC.

Here, we present the detailed diagnosis and DNA-sequencing profile of a PRCC that displays a unique (imaging and gross) intra-pyelocalyceal growth pattern, mimicking a urothelial cell carcinoma of the renal pelvis.

2. Case Presentation

A 59-year-old male patient with a history of Type II diabetes mellitus, renal–ureteral lithiasis, and benign prostate hypertrophy was admitted to the emergency room with macroscopic hematuria. Following a urologic computed tomography (CT) scan, the patient was diagnosed with a right renal mass measuring 3.6 cm in diameter, with a possible diagnosis of urothelial carcinoma of the renal pelvis (Figure 1). Next, a flexible ureteroscopy was performed with visualization of the urinary bladder, the entire tract of the right ureter, which revealed normal-appearing mucosa, and the right renal pelvis where a reddish mass was identified; the mass was described as difficult to ascertain for positioning due to difficulties in acquisition and visualization.

A surgical intervention for a right total nephrectomy was chosen as the treatment of choice by the surgical department, with follow-up surgical reintervention if needed. The patient was assigned to the high-risk category of upper-urinary tract urothelial-cell carcinoma (UUTC), based on the 2018 European Association of Urology (EAU) guidelines [5], because of the tumor size of more than 2 cm and signs of hydronephrosis. No cytology or histology confirmation was performed before the surgical intervention.

The pathological grossing of the kidney revealed a small nodular lesion located medially, near the corticomedullary boundary, extending in a cordon-like manner from the minor calyces to the ureteropelvic junction and proximal ureter (Figure 1). The H&E stain showed microscopically that the tumor was composed of small cuboidal cells with inconspicuous nucleoli, arranged on a single layer of tubulo-papillary cores. The tumor stroma was noted for scant foamy macrophages (Figure 1). The tumor had a non-infiltrative, expansive pyelocalyceal growth. Immunohistochemically (IHC), the tumor cells were CK7-intense and diffusely positive, stained granular for alpha-methyl acyl-CoA racemase (AMACR), (Figure 1), and negative for Wilms tumor protein (WT1) (not shown).
Figure 1. A selected panel of images containing representative snapshots of the tumor from CT to IHC. (A) Selected section from the contrast-enhanced CT of the abdomen that showed an hypo-enhancing nodular lesion in the right kidney that measured approximately 38 × 26 × 21 mm (green star on the bivalved nephrectomy surgical specimen while grossing); delayed scan of the lesion that showed the apparent invasion of the renal pelvis (red arrow); (B) Pathological grossing of the nephrectomy surgical specimen, bivalved section, that shows a nodular lesion of approximately 3 × 2 × 2 cm located medially, near the corticomedullary boundary; further sections revealed that the nodular lesion was in communication with the cordon-like tumor that shows an intra-pyelocalyceal (non-invasive and compressive) growth pattern (demarcated with dashed white lines), extending all the way to the opening of the proximal ureter; (C) H&E section from the renal pelvis showing the cordon-like (demarcated with dashed red lines), red dashed arrow indicates the section origin; (D) H&E section from the nodular lesion (demarcated with dashed blue lines), blue dashed arrow indicates the section origin; (E) H&E section from the renal pelvis showing the tumor composed of tubulo-papillary structures, the red star indicates the section corresponding to the red star on image (C); the black arrow indicates normal urothelium; (F) H&E section with higher magnification of the nodular lesion showing compact tubulo-papillary structures lined single layer small cuboidal cells with inconspicuous nucleoli, black dashed circle indicates foamy macrophages; blue star indicates the section corresponding to the blue star on image (D); (G) IHC for CK7 showing intense and diffusely positive stain both in the tumor and in the urothelium indicated by the black arrow; (H) Higher magnification of IHC for CK7 showed in image (G), the red star indicates the section corresponding to the red star on image (G); the black arrow indicates the urothelium positive for CK7; (I) IHC for AMACR showing positive granular stained tumor cells, with negatively stained urothelium marked by the black arrow; the red star indicates the section corresponding to the red star on image (H).

After the pathology report was completed with a diagnosis of type I PRCC WHO ISUP (2016)/PRCC WHO ISUP (2022)—G1, pT1b, one representative slide was chosen, and two areas were marked; one tumor area and one histologically normal area. Next, the corresponding formalin-fixed paraffin-embedded (FFPE) tissue block was used to extract, with the use of a 0.1 mm punch biopsy instrument, the corresponding areas marked on the H&E slide, and the two extracted cores were subsequently processed for NGS. NGS
was chosen to try to clarify the mutational background underpinning the unique growth pattern seen in the tumor.

Briefly, the following protocol was used for the NGS: (1) DNA purification—GeneJET Genomic DNA Purification Kit (ThermoFisher Scientific Inc., Waltham, MA, USA); (2) Library Preparation—Ion Ampliseq™ Library Preparation on the Ion Chef System + Ampliseq™ Cancer Hotspot Panel v2 Chef-Ready Kit (ThermoFisher Scientific); (3) Automated template preparation, chip loading, and sequencing—Ion 510 and Ion 520 and Ion 530 Kit—Chef + Ion GeneStudio S5 System; (4) Analysis—Ion Reporter and Oncomine Reporter (ThermoFisher Scientific Inc., Waltham, MA, USA).

The NGS results considered to be somatic were the ones that showed an allele frequency below 50%, and any genomic alterations detected that showed an allele frequency above 50% were considered germline [5]. The main somatic genomic alterations both from the histologically normal tissue and the tumor tissue are represented in Tables 1 and 2. All of the detected genomic alterations, both somatic and germline, are included in the Supplementary Materials. The histologically normal tissue was remarkable for the genomic alterations in the following genes: TP53; ABL1; ERBB4; PIK3CA; KIT; EGFR; MET; GNAQ; RET; FGFR2; ATM; and CDH1. The tumor was remarkable for genomic alterations in the following genes: TP53; SMAD4; VHL; PIK3CA; FGFR3; PDGFRA; KIT; KDR; FBXW7; APC; ATM; PTPN11; FLT3; RB1; AKT1; CDH1; ERBB2; STK11.

Table 1. Genomic alterations that were detected in the histologically normal tissue. Allele frequency below 50% was considered a somatic mutation [6]. No synonymous variants were included in the table even if the allele frequency was below 50%, but are included in the Supplementary Materials. * Automatic reporting from Ion Reporter and Oncomine Reporter of mutations for the most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

| Genomic Alteration | Gene | Amino Acid Change | Coding | Locus | Allele Frequency | Variant Effect |
|--------------------|------|-------------------|--------|-------|-----------------|---------------|
| TP53 D208G         | TP53 | p.(D208G)         | c.623A > G | chr17:7578226 | 4.10%            | missense      |
| ABL1 M244I         | ABL1 | p.(M244I)         | c.732G > A | chr9:133738332 | 11.00%           | missense      |
| ERBB4 V167A        | ERBB4| p.(V167A)         | c.500T > C | chr2:212652806 | 3.08%            | missense      |
| PIK3CA M1043*      | PIK3CA| p.(M1043*)        | c.3127delA | chr3:178952069 | 0.36%            | nonsense      |
| KIT L644P          | KIT  | p.(L644P)         | c.1931T > C | chr4:55594228 | 25.96%           | missense      |
| EGFR G575R         | EGFR | p.(G575R)         | c.1723G > A | chr7:55232973 | 42.57%           | missense      |
| MET T1011A         | MET  | p.(T1011A)        | c.3031A > G | chr7:116411992 | 3.83%            | missense      |
| GNAQ D236G         | GNAQ | p.(D236G)         | c.707A > G | chr9:80409407 | 3.20%            | missense      |
| RET P785L          | RET  | p.(P785L)         | c.2354G > T | chr10:43613890 | 4.31%            | missense      |
| FGFR2 E368G         | FGFR2| p.(E368G)         | c.1103A > G | chr10:123274815 | 6.94%            | missense      |
| ATM S333F          | ATM  | p.(S333F)         | c.998C > T | chr11:10817787 | 25.49%           | missense      |
| ATM H1688V         | ATM  | p.(H1688V)        | c.5062A > G | chr11:10817047 | 4.50%            | missense      |
| CDH1 T66A          | CDH1 | p.(T66A)          | c.196A > G | chr16:68835605 | 8.70%            | missense      |

Table 2. Genomic alterations that were detected in the tumor tissue. Allele frequency below 50% was considered a somatic mutation [6]. No synonymous variants were included in the table even if the allele frequency was below 50%, but are included in the Supplementary Materials. * Automatic reporting from Ion Reporter and Oncomine Reporter of mutations for the most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

| Genomic Alteration | Gene | Amino Acid Change | Coding | Locus | Allele Frequency | Variant Effect |
|--------------------|------|-------------------|--------|-------|-----------------|---------------|
| TP53 I254T         | TP53 | p.(I254T)         | c.761T > C | chr17:7577520 | 7.68%            | missense      |
| TP53 S241P         | TP53 | p.(S241P)         | c.721T > C | chr17:7577560 | 2.31%            | missense      |
| SMAD4 H444W,R445*   | SMAD4| p.(H444W,R445*)   | c.1330_1333delCATCinsTGGT | chr18:48603029 | 22.22%           | missense, nonsense |
| VHL Y156H          | VHL  | p.(Y156H)         | c.466T > C | chr3:10191473 | 3.57%            | missense      |
| PIK3CA D84N         | PIK3CA| p.(D84N)          | c.250G > A | chr3:178916863 | 10.91%           | missense      |
| FGFR3 G773S         | FGFR3| p.(G773S)         | c.2317G > A | chr4:1808885  | 5.32%            | missense      |
The patient was evaluated at 3, 6, and 12 months after the nephrectomy procedure with no signs of cancer recurrence and no signs of metastasis. Presently, at 4 years of follow-up, the patient is well and cancer-free.

3. Discussion

In this case presentation, we demonstrate a unique growth pattern of PRCC (WHO 2022) presenting in a 59-year-old male patient and subsequently provide a mutational signature of the histologically normal kidney tissue and tumor tissue, using NGS to further explore the molecular basis of this unique presentation. While many of the growth patterns are described in the literature for PRCC [1,4,7,8], to our knowledge no other case similar to this one is characterized in the scientific literature.

Regarding the surgical treatment of choice, the 2018 EAU guidelines recommend radical nephroureterectomy (RNU) for confirmed UUTC [5]; nevertheless, in our case, the suspicion of urothelial carcinoma of the renal pelvis based on urologic CT and no mucosal abnormalities detected in the presurgical ureteroscopy favored the choice of radical nephrectomy.

Next, after the pathology report, based on the available data and the guidelines used in 2018 [9], the patient outcome was considered excellent. The follow-up was stratified at 3, 6, and 12 months for renal function tests, local recurrence, recurrence in the contralateral kidney, and metastases. At 12 months post-surgical intervention, 6 month follow-ups were implemented, with presently, at 4 years after diagnosis, the patient remaining stable with no abnormalities in the kidney function tests and no signs of tumor recurrence. In our case, the renal mass was approachable for a preoperative biopsy strategy, unfortunately, no biopsy of the tumor mass was performed before nephrectomy as per the internal surgical protocols available at the time of the surgical intervention. While currently the diagnostic accuracy of a preoperative biopsy in suspected renal masses is estimated at around 98%, with less than 1% risk of bleeding, this management strategy remains underutilized [10]. This high diagnostic yield is estimated to solidify, as more technological breakthroughs are implemented, i.e., confocal fluorescence microscopy, specifically for preoperative biopsies.

| Genomic Alteration | Gene | Amino Acid Change | Coding | Locus | Allele Frequency | Variant Effect |
|--------------------|------|-------------------|--------|-------|-----------------|---------------|
| PDGFRA R554G       | PDGFRA| p.(R554G)         | c.1660A > G | chr4:55141014 | 5.76% | missense |
| KIT                | KIT  | p.(?)             | c.1991-2_1991-1delinsC.A | chr4:55995499 | 3.57% | unknown |
| KIT                | KIT  | p.(?)             | c.1991-2_1991delinsCCC. | chr4:55995499 | 96.43% | unknown |
| KDR P479A          | KDR  | p.(P479A)         | c.1435C > G | chr4:55141014 | 28.57% | missense |
| FBXW7 L594V        | FBXW7| p.(L594V)         | c.1780C > G | chr4:153245411 | 66.67% | missense |
| APC L1342S         | APC  | p.(L1342S)        | c.4025T > C | chr5:112175316 | 6.25% | missense |
| ATM D408E,L409N    | ATM  | p.([D408E,L409N])| c.1224_1227delCTTinsGAAC | chr11:108119818 | 13.51% | missense, missense |
| PTPN11 I494V       | PTPN11| p.(I494V)         | c.1480A > G | chr12:112926860 | 7.85% | missense |
| FLT3 L610V         | FLT3 | p.(L610V)         | c.1828T > G | chr13:28608228 | 9.80% | missense |
| FLT3 N609T         | FLT3 | p.(N609T)         | c.1826A > C | chr13:28608230 | 5.04% | missense |
| FLT3 E608V         | FLT3 | p.(E608V)         | c.1823A > T | chr13:28608233 | 10.39% | missense |
| FLT3               | FLT3| p.(?)             | c.1310-2A > G | chr13:28610182 | 40.00% | unknown |
| R1B E554G          | R1B  | p.(E554G)         | c.1661A > G | chr13:48955545 | 10.95% | missense |
| R1B Q689R,N690Y    | R1B  | p.([Q689R,N690Y])| c.2066_2068delCTTinsGAAC | chr13:49033929 | 5.17% | missense, missense |
| AKT1 P42S          | AKT1 | p.(P42S)          | c.124C > T | chr14:105246476 | 3.30% | missense |
| CDH1 N93S          | CDH1 | p.(N93S)          | c.278A > G | chr16:6883587 | 14.83% | missense |
| TP53 S20P          | TP53 | p.(S20P)          | c.58T > C | chr17:7597985 | 9.89% | missense |
| ERBB2 V794M        | ERBB2| p.(V794M)         | c.2380G > A | chr17:37881051 | 4.85% | missense |
| STK11 E33K         | STK11| p.(E33K)          | c.97G > A | chr19:1207009 | 3.15% | missense |
in urological cancers, this, however, would only be implementable in urological centers with high resources and solid surgical infrastructures [11,12].

Briefly, considering the normal anatomy and micro-anatomy of the kidney [13], the initial tumor most probably developed at the boundary between the renal cortex and the renal medulla and expanded slowly, first as a tumor nodule and then, upon invading a collecting duct, it grew in a cord-like manner till it reached the papillary duct. This provided the expanding tumor access to, and subsequent growth in, the minor and major calyx, and finally the renal pelvis. Here, constant erosion and shedding of the tumor mass elicited the macroscopic hematuria with which the patient presented in the emergency room. The factual basis for the lack of frank invasion of the tumor into the neighboring normal kidney tissue is probably owing to the fact that this uniquely presenting tumor was a low-grade PRCC [4,7]. Considering the somatic genomic alterations identified in the histologically normal tissue (Table 1), we can regard all of the variants identified as contributors to the eventual formation of the tumor, more so when compared with the data in the literature where, specifically, TP53, EGFR, CDH1, and MET mutations can be viewed as the initial drivers for tumor genesis, progression, and invasion [14].

The genomic alterations identified in the tumor tissue are in line with the TCGA published dataset on PRCC [2], specifically the presence of a mutation in VHL identified in the tumor can be considered a “marker” of type I PRCC (WHO 2016). Interestingly, the presence of mutations identified in the SMAD4, FGFR3, PDGFRA, APC, ATM, KIT, RB1, CDH1, and PIK3CA are all known genes with roles in carcinoma development and progression [15], but with low evidence for a contribution to PRCC [2]. Furthermore, no mutations were detected in the KDM6A, SMARCB1, and NFL2L2, as previously described as representative of type 1 PRCC (WHO 2016) [2]. These results can be explained by the low grade of the tumor, which translates into a low mutational burden or mutations that show weak tumor-driver ability. In addition, the heterogeneity in the mutations identified in our case, and the fact that it did not fit with the reported NGS data, provides further background to the concept of a landscape or wide spectrum of tumors in the PRCC family [4]. To further clarify the blurring lines in the spectrum of PRCC, some interesting markers have been demonstrated, specifically, the biomarkers delineating differential diagnosis, i.e., the microRNA—miR-21 increased expression in tissue, and the risk of metastasis i.e., the insulin-like growth factor II mRNA-binding protein 3 (IMP3) increased expression in tissue [16,17].

Finally, considering the low aggressiveness of the tumor, which can be conceptualized by the fact that the tumor most probably had a long growth with regards to the timeframe of development, and no frank invasion of the neighboring kidney tissue, places this particular PRCC on the low-aggressive part of the spectrum of PRCC.

The limiting part of our case report is that we did not evaluate the presence of copy gains in chromosome 7, which represent the particular signature found in the WHO 2016 subdivision which identifies the mutational background in type 1 PRCC. Another limiting factor for our case report is the lack of a multi-omics approach, specifically, transcriptome sequencing, epigenome sequencing, and non-coding RNA sequencing. These NGS methods would offer invaluable insights into the progression of low-grade, non-invasive PRCC to high-grade, frank-invasive PRCC, and the surrounding normal tissue molecular portrait in association with these neoplasms [18]. This testing methodology could be employed to offer better tumorigenesis and tumor progression biomarkers.

In conclusion, we describe the unique growth pattern of this PRCC from CT to NGS and provide a succinct discussion on the pathological background underpinning this particular presentation.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12081904/s1, Table S1: All genomic alterations detected in the histologically normal tissue. Table S2: All genomic alterations detected in the tumor tissue.
Author Contributions: Conceptualization, O.O.H., G.-E.O. and I.M.M.; methodology, F.M.B. and G.O.I.; validation, F.M.B. and G.O.I.; formal analysis, O.O.H., I.M.M. and G.-E.O.; investigation, G.-E.O., I.M.M., F.M.B. and G.O.I.; resources, P.V.; data curation, I.M.M. and F.M.B.; writing—original draft preparation, O.O.H. and G.-E.O.; writing—review and editing, O.O.H., G.-E.O., I.M.M., G.O.I., F.M.B. and M.B.; visualization, G.-E.O. and M.B.; supervision, F.M.B.; project administration, P.V.; funding acquisition, P.V. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was supported by the “Victor Babes” University of Medicine and Pharmacy Timisoara.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, but ethical review and approval were waived for this retrospective case report, which did not impact the management of the patient.

Informed Consent Statement: Informed consent was obtained from the subject involved in the case report.

Data Availability Statement: All of the data are available upon request to the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Moch, H.; Cubilla, A.L.; Humphrey, P.A.; Reuter, V.E.; Ulbright, T.M. The 2016 WHO classification of tumours of the urinary system and male genital organs—Part A: Renal, penile, and testicular tumours. Eur. Urol. 2016, 70, 93–105. [CrossRef] [PubMed]
2. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N. Engl. J. Med. 2016, 374, 135–145. [CrossRef] [PubMed]
3. Ljungberg, B.; Albigeis, L.; Abu-Ghanem, Y.; Bensalah, K.; Dabestani, S.; Fernández-Pello, S.; Giles, R.H.; Hofmann, F.; Hora, M.; Kuczyk, M.A.; et al. European association of urology guidelines on renal cell carcinoma: The 2019 update. Eur. Urol. 2019, 75, 799–810. [CrossRef] [PubMed]
4. Lobo, J.; Ohashi, R.; Amin, M.B.; Berney, D.M.; Compérat, E.M.; Cree, I.A.; Gill, A.J.; Hartmann, A.; Menon, S.; Netto, G.J.; et al. The WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology 2022. [CrossRef] [PubMed]
5. Rouprêt, M.; Babjuk, M.; Compérat, E.; Zigeuner, R.; Sylvester, R.J.; Burger, M.; Cowan, N.C.; Gontero, P.; Van Rhijn, B.W.; Mostafid, A.H.; et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur. Urol. 2018, 73, 111–122. [CrossRef] [PubMed]
6. He, M.M.; Li, Q.; Yan, M.; Cao, H.; Hu, Y.; He, K.Y.; Cao, K.; Li, M.M.; Wang, K. Variant Interpretation for Cancer (VIC): A computational tool for assessing clinical impacts of somatic variants. Genome Med. 2019, 11, 53. [CrossRef] [PubMed]
7. Mendhiratta, N.; Muraki, P.; Sisk, A.E., Jr.; Shuch, B. Papillary renal cell carcinoma. In Urologic Oncology: Seminars and Original Investigations; Elsevier: Amsterdam, The Netherlands, 2021; Volume 39, pp. 327–337.
8. Williamson, S.R. Clear cell papillary renal cell carcinoma: An update after 15 years. Pathology 2021, 53, 109–119. [CrossRef] [PubMed]
9. Ljungberg, B.; Albigeis, L.; Bensalah, K.; Bex, A.; Giles, R.H.; Hora, M.; Kuczyk, M.A.; Lam, T.; Marconi, L.; Merseburger, A.S.; et al. EAU guidelines on renal cell carcinoma 2018. Euro. Urol. 2018, 29, 451–458.
10. McClure, T.; Sedrakyan, A.; LaRussa, S.; Sun, T.; Mao, J.; Del Pizzo, J.; Hu, J. Underutilization of renal mass biopsy: Surveillance using the medicare database between 2004 and 2016. J. Vasc. Interv. Radiol. JVir 2020, 31, 854–857. [CrossRef] [PubMed]
11. Mir, M.C.; Bancalari, B.; Calatrava, A.; Casanova, J.; Escrig, J.-L.D.; Ramirez-Backhaus, M.; Gomez-Ferrer, A.; Collado, A.; Wong, A.; Iborra, I.; et al. Ex-vivo confocal fluorescence microscopy for rapid evaluation of renal core biopsy. Minerva Urol. E Nefrol. Ital. J. Urol. Nephrol. 2019, 72, 109–113. [CrossRef] [PubMed]
12. Marenco, J.; Calatrava, A.; Casanova, J.; Claps, F.; Mascaros, J.; Wong, A.; Barrios, M.; Martin, I.; Rubio, J. Evaluation of fluorescent confocal microscopy for intraoperative analysis of prostate biopsy cores. Eur. Urol. Focus 2021, 7, 1254–1259. [CrossRef] [PubMed]
13. I. Mescher, A. The Urinary System. In Junqueira’s Basic Histology Text and Atlas, 15th ed.; McGraw-Hill Education: New York, NY, USA, 2018; p. 407.
14. Pan, H.; Ye, L.; Zhu, Q.; Yang, Z.; Hu, M. The effect of the papillary renal cell carcinoma subtype on oncological outcomes. Sci. Rep. 2020, 10, 21073. [CrossRef] [PubMed]
15. Alexandrov, L.B.; Kim, J.; Haradhvala, N.J.; Huang, M.N.; Tian Ng, A.W.; Wu, Y.; Boot, A.; Covington, K.R.; Gordenin, D.A.; Bergstrom, E.N.; et al. The repertoire of mutational signatures in human cancer. Nature 2020, 578, 94–101. [CrossRef] [PubMed]
16. Kapoor, J.; Claps, F.; Mir, M.C.; Ischia, J. Promising Biomarkers in Renal Cell Carcinoma. Société Int. D’urologie J. 2021, 2, 43–52. [CrossRef]
17. Claps, F.; Mir, M.C. Novel expanding renal cell carcinoma biomarkers. Société Int. D’urologie J. 2021, 2, 32–42. [CrossRef]
18. Rysz, J.; Franczyk, B.; Lawiński, J.; Głąba-Brzozka, A. Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC). Int. J. Mol. Sci. 2021, 23, 151. [CrossRef] [PubMed]